Association of the MTHFR C677T polymorphism and bone mineral density in postmenopausal women: a meta-analysis
- PMID: 23554658
- PMCID: PMC3596689
- DOI: 10.1016/S1674-8301(10)60056-5
Association of the MTHFR C677T polymorphism and bone mineral density in postmenopausal women: a meta-analysis
Abstract
Osteoporosis is a condition characterized by low bone mineral density (BMD) and micro-architectural changes in the bone tissue. The risk of osteoporosis is partly determined by genetic factors. The role of C677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene has been investigated in postmenopausal osteoporosis. However, the relationship between MTHFR polymorphism and BMD is still controversial. We carried out a meta-analysis of 5,833 subjects to evaluate the association of MTHFR and BMD in postmenopausal women. Databases of MEDLINE, Web of Science, Scopus and CNKI were retrieved for all publications relating to MTHFR polymorphism and BMD in postmenopausal women. Five eligible studies were selected for meta-analysis. All these articles studied the association of MTHFR polymorphism and BMD of the femoral neck and lumbar spine in postmenopausal women. Our analysis suggested that postmenopausal women with the TT genotype had lower femoral neck BMD than the women with the CC/CT genotype, and the weighted mean difference (WMD) was -0.01 g/cm(2) [95% confidence interval (CI): (-0.01, -0.01), P < 0.01]. However, BMD of the lumbar spine of postmenopausal women with the TT genotype was not significantly different from that of women with the CC/CT genotype. In the random effects model, the WMD between the TT and TC/CC genotype was -0.01 g/cm(2) [95% CI: (-0.04, 0.01), P = 0.32]. The C677T polymorphism of the MTHFR gene is associated with BMD of the femoral neck in postmenopausal women. Women with the TT genotype of the MTHFR gene have lower BMD, suggesting that the TT genotype may be a risk factor for postmenopausal osteoporosis.
Keywords: bone mineral density; meta-analysis; methylenetetrahydrofolate reductase; postmenopausal women.
Conflict of interest statement
The authors reported no conflict of interest.
Figures

Similar articles
-
Association of MTHFR C667T polymorphism with bone mineral density and fracture risk: an updated meta-analysis.Osteoporos Int. 2012 Nov;23(11):2625-34. doi: 10.1007/s00198-011-1885-6. Epub 2011 Dec 21. Osteoporos Int. 2012. PMID: 22187009
-
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with osteoporotic vertebral fractures, but is a weak predictor of BMD.Osteoporos Int. 2005 Apr;16(4):411-6. doi: 10.1007/s00198-004-1704-4. Epub 2004 Aug 6. Osteoporos Int. 2005. PMID: 15300362
-
Association between the methylenetetrahydrofolate reductase c.677C>T polymorphism and bone mineral density: an updated meta-analysis.Mol Genet Genomics. 2016 Feb;291(1):169-80. doi: 10.1007/s00438-015-1101-z. Epub 2015 Aug 1. Mol Genet Genomics. 2016. PMID: 26231982
-
Polymorphisms in the Runx2 and osteocalcin genes affect BMD in postmenopausal women: a systematic review and meta-analysis.Endocrine. 2024 Apr;84(1):63-75. doi: 10.1007/s12020-023-03621-2. Epub 2023 Dec 6. Endocrine. 2024. PMID: 38055125
-
Meta-analysis of walking for preservation of bone mineral density in postmenopausal women.Bone. 2008 Sep;43(3):521-31. doi: 10.1016/j.bone.2008.05.012. Epub 2008 May 26. Bone. 2008. PMID: 18602880
Cited by
-
Genetic variants of MTHFR gene in relation to folic acid levels and bone mineral density in Polish patients with inflammatory bowel disease.J Appl Genet. 2024 Feb;65(1):73-81. doi: 10.1007/s13353-023-00792-6. Epub 2023 Oct 11. J Appl Genet. 2024. PMID: 37816983 Free PMC article.
-
Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications?Nutrients. 2021 Nov 12;13(11):4036. doi: 10.3390/nu13114036. Nutrients. 2021. PMID: 34836291 Free PMC article. Review.
-
Influence of homocysteine and its major genetic and nutritional determinants on bone mineral density.Tunis Med. 2022 juillet;100(7):514-519. Tunis Med. 2022. PMID: 36571739 Free PMC article.
-
Vitamin B12, folic acid, and bone.Curr Osteoporos Rep. 2013 Sep;11(3):213-8. doi: 10.1007/s11914-013-0155-2. Curr Osteoporos Rep. 2013. PMID: 23873438 Review.
-
Association of Methylenetetrahydrofolate Reductase rs1801133 Polymorphism with osteoporosis and fracture risk in Taiwan.Int J Med Sci. 2024 Aug 19;21(12):2261-2271. doi: 10.7150/ijms.97524. eCollection 2024. Int J Med Sci. 2024. PMID: 39310265 Free PMC article.
References
-
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95. - PubMed
-
- Seeman E, Eisman JA. Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust. 2004;180:298–303. - PubMed
-
- North American Menopause Society Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13:340–67. - PubMed
LinkOut - more resources
Full Text Sources